A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04706637
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT04706637
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT04706637. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
- Acronym
- EVOMETA
- Condition
- Bone Diseases, Metabolic
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Evogliptin
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Kyung Hee University Hospital at Gangdong
- Collaborator
- Dong-A ST Co., Ltd.
Record details
- Record id
cardio:ct-nct04706637- Content hash
5592811afc2f72ddc3a66c1f0974bed5608576f3cc5fdcf2a67982b43c95a263